KPTI
Karyopharm Therapeutics Inc
1.60$
-6.4%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -82.0% | -55.1% | -132.0% | -90.0% | -50.2% | -84.5% | -129.9% | -49.3% | -13.3% | -34.7% | -64.8% | -74.6% | -44.6% | |
| 0.8% | 0.9% | 0.9% | 0.2% | 6.4% | 8.0% | 0.3% | -0.1% | 0.3% | 7.2% | 0.0% | 0.0% | 1.8% | |
| 14.1% | 15.4% | 15.0% | 12.6% | 10.8% | 12.7% | 11.9% | 10.0% | 6.4% | 11.5% | 8.6% | 5.8% | 7.9% | |
| 5.3% | 49.2% | -38.1% | -22.1% | 19.3% | 33.0% | -5.1% | 26.5% | 32.3% | 16.1% | 11.0% | 3.8% | 17.0% | |
| 0.0% | 0.0% | 0.6% | 0.0% | 0.0% | 0.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| -21.3% | 79.5% | 66.2% | 119.8% | 19.3% | 48.4% | 50.9% | 48.2% | 10.9% | 14.7% | 9.1% | -30.0% | 2.0% | |
| – | – | – | – | 286.2% | – | – | – | – | – | – | – | – | |
| – | – | – | – | 0.0% | 132.7% | – | – | 0.0% | 79.2% | – | – | – | |
| 107.1% | 0.8% | – | 95.7% | 0.0% | 2.2% | 0.0% | 0.9% | 0.0% | 87.1% | 142.0% | -2.7% | 53.6% | |
| -103.5% | 25.5% | -65.8% | 125.6% | -30.8% | -33.9% | -78.9% | -0.1% | -2.4% | 67.1% | 86.4% | -107.3% | 11.1% | |
| -82.0% | -55.1% | -132.6% | -90.0% | -50.2% | -84.3% | -129.9% | -49.3% | -13.3% | -34.7% | -64.8% | -74.6% | -44.6% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.